Guyasuta Investment Advisors Inc. Invests $724,000 in Waters Corporation $WAT

Guyasuta Investment Advisors Inc. bought a new stake in Waters Corporation (NYSE:WAT) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,431 shares of the medical instruments supplier’s stock, valued at approximately $724,000.

Other large investors have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT increased its stake in Waters by 121.2% during the 4th quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 40 shares during the period. SHP Wealth Management purchased a new position in Waters in the 4th quarter valued at about $32,000. DV Equities LLC acquired a new stake in shares of Waters during the fourth quarter valued at about $32,000. Western Pacific Wealth Management LP acquired a new stake in shares of Waters during the first quarter valued at about $47,000. Finally, eCIO Inc. purchased a new stake in shares of Waters during the fourth quarter worth about $49,000. 94.01% of the stock is owned by institutional investors and hedge funds.

Waters Stock Performance

Shares of WAT stock opened at $356.82 on Wednesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.13 and a current ratio of 1.79. Waters Corporation has a one year low of $275.05 and a one year high of $414.15. The company’s 50-day simple moving average is $344.19 and its 200-day simple moving average is $347.65. The stock has a market capitalization of $35.04 billion, a price-to-earnings ratio of 45.34, a PEG ratio of 2.17 and a beta of 1.21.

Waters (NYSE:WAT) last posted its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.31 by $0.39. The business had revenue of $1.27 billion during the quarter, compared to the consensus estimate of $1.20 billion. Waters had a return on equity of 15.60% and a net margin of 11.91%.The company’s revenue for the quarter was up 91.4% compared to the same quarter last year. During the same period last year, the firm earned $2.25 earnings per share. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Equities analysts anticipate that Waters Corporation will post 14.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on WAT shares. Wells Fargo & Company increased their price target on Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Bank of America lifted their price objective on Waters from $370.00 to $400.00 and gave the stock a “neutral” rating in a report on Tuesday, June 2nd. The Goldman Sachs Group raised Waters to a “strong-buy” rating in a research report on Wednesday, April 1st. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $350.00 target price on shares of Waters in a research note on Thursday, May 7th. Finally, Robert W. Baird set a $387.00 price target on shares of Waters in a research report on Wednesday, May 6th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Waters currently has an average rating of “Moderate Buy” and a consensus price target of $394.56.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.